ATE223728T1 - Stabilisierte pharmazeutische zusammensetzung von bdnf - Google Patents

Stabilisierte pharmazeutische zusammensetzung von bdnf

Info

Publication number: ATE223728T1
Authority: AT; Austria
Prior art keywords: bdnf; pct; pharmaceutical composition; sec; lyophilized
Prior art date: 1996-05-27

Application number

AT97922156T

Other languages

English (en)

Inventor

Kaatsumi Tanaka

Masashi Kumano

Original Assignee

Regeneron Pharma

Sumitomo Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-27

Filing date

1997-05-26

Publication date

2002-09-15

1997-05-26 Application filed by Regeneron Pharma, Sumitomo Pharma filed Critical Regeneron Pharma

2002-09-15 Application granted granted Critical

2002-09-15 Publication of ATE223728T1 publication Critical patent/ATE223728T1/de

Links

102000004219 Brain-derived neurotrophic factor Human genes 0.000 title abstract 5
108090000715 Brain-derived neurotrophic factor Proteins 0.000 title abstract 5
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
229940077737 brain-derived neurotrophic factor Drugs 0.000 abstract 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
230000036425 denaturation Effects 0.000 abstract 1
238000004925 denaturation Methods 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000002736 nonionic surfactant Substances 0.000 abstract 1
238000006116 polymerization reaction Methods 0.000 abstract 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
229920000053 polysorbate 80 Polymers 0.000 abstract 1
150000005846 sugar alcohols Chemical class 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

AT97922156T 1996-05-27 1997-05-26 Stabilisierte pharmazeutische zusammensetzung von bdnf ATE223728T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP8156070A JPH10212241A (ja)	1996-05-27	1996-05-27	Ｂｄｎｆを安定に含有する製剤
PCT/JP1997/001746 WO1997045135A1 (en)	1996-05-27	1997-05-26	Stable pharmaceutical composition of bdnf

Publications (1)

Publication Number	Publication Date
ATE223728T1 true ATE223728T1 (de)	2002-09-15

Family

ID=15619654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97922156T ATE223728T1 (de)	1996-05-27	1997-05-26	Stabilisierte pharmazeutische zusammensetzung von bdnf

Country Status (11)

Country	Link
US (1)	US6077829A (de)
EP (1)	EP0910399B1 (de)
JP (1)	JPH10212241A (de)
AT (1)	ATE223728T1 (de)
AU (1)	AU715571B2 (de)
CA (1)	CA2256410C (de)
DE (1)	DE69715414T2 (de)
DK (1)	DK0910399T3 (de)
ES (1)	ES2183170T3 (de)
PT (1)	PT910399E (de)
WO (1)	WO1997045135A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998010785A1 (en) *	1996-09-13	1998-03-19	Advanced Medicine Research Institute	Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
US20040120891A1 (en) *	1998-12-21	2004-06-24	Craig Hill	Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU5105100A (en) *	1999-06-03	2000-12-28	Eisai Co. Ltd.	Crystals of carbapenem derivatives and pharmaceutical preparations for injection
AUPQ084899A0 (en) *	1999-06-08	1999-07-01	University Of Melbourne, The	Neurotrophin agonists
AU2001271037A1 (en) *	2000-07-13	2002-01-30	Daiichi Pharmaceutical Co., Ltd.	Pharmaceutical compositions containing dds compounds
US6852323B2 (en)	2000-07-21	2005-02-08	The Regents Of The University Of California	Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) *	2000-07-21	2007-05-29	The Regents Of The University Of California	Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002096356A2 (en) *	2001-05-25	2002-12-05	Cornell Research Foundation, Inc.	HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
DE10149030A1 (de) *	2001-10-05	2003-04-10	Viscum Ag	Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20040096828A1 (en) *	2002-01-04	2004-05-20	Lu Dyung Aina M	Cytoskeleton-associated proteins
US20030219696A1 (en) *	2002-05-23	2003-11-27	Moreland Gerald W.	Method and apparatus for preventing backflow in dental saliva evacuators
CA2513226A1 (en) *	2003-01-13	2004-07-29	Mahendra S. Rao	Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US20050048041A1 (en) *	2003-01-13	2005-03-03	Rao Mahendra S.	Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
MX2007015292A (es)	2005-06-06	2008-02-21	Wyeth Corp	Anticuerpos monoclonales anti-trkb y sus usos.
CN103301475B (zh)	2005-12-28	2016-08-03	斯克里普斯研究所	药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
WO2008019431A1 (en) *	2006-08-14	2008-02-21	Brc Operations Pty Limited	Method and compositions for simultaneously regulating memory and mood
IT1396607B1 (it)	2009-11-16	2012-12-14	Hmfra Hungary Ltd Liability Company	Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso.
CA2781666C (en)	2009-11-23	2017-02-21	Cubist Pharmaceuticals, Inc.	Lipopeptide compositions and related methods
ES2694592T3 (es)	2012-03-15	2018-12-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
MX2021000644A (es)	2018-07-18	2021-08-19	Manzanita Pharmaceuticals Inc	Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
JP2021019532A (ja) *	2019-07-26	2021-02-18	花王株式会社	血液脳関門保護剤
EP4117625A1 (de)	2020-03-12	2023-01-18	Baxter International Inc.	Daptomycin-formulierungen mit einer kombination aus sorbitol und mannitol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5180820A (en) *	1989-08-30	1993-01-19	Barde Yves Alain	Brain-derived neurotrophic factor
AU6909091A (en) *	1989-12-05	1991-06-26	Ramsey Foundation	Neurologic agents for nasal administration to the brain
US5604202A (en) *	1990-11-13	1997-02-18	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Use of NGF growth factors to treat drug-induced neuropathy
US5770577A (en) *	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol

1996
- 1996-05-27 JP JP8156070A patent/JPH10212241A/ja active Pending
1997
- 1997-05-26 US US09/180,884 patent/US6077829A/en not_active Expired - Fee Related
- 1997-05-26 WO PCT/JP1997/001746 patent/WO1997045135A1/en not_active Ceased
- 1997-05-26 EP EP97922156A patent/EP0910399B1/de not_active Expired - Lifetime
- 1997-05-26 ES ES97922156T patent/ES2183170T3/es not_active Expired - Lifetime
- 1997-05-26 PT PT97922156T patent/PT910399E/pt unknown
- 1997-05-26 AU AU27923/97A patent/AU715571B2/en not_active Ceased
- 1997-05-26 DK DK97922156T patent/DK0910399T3/da active
- 1997-05-26 DE DE69715414T patent/DE69715414T2/de not_active Expired - Lifetime
- 1997-05-26 AT AT97922156T patent/ATE223728T1/de not_active IP Right Cessation
- 1997-05-26 CA CA002256410A patent/CA2256410C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69715414T2 (de)	2003-05-15
CA2256410C (en)	2007-02-27
AU2792397A (en)	1998-01-05
US6077829A (en)	2000-06-20
EP0910399A1 (de)	1999-04-28
CA2256410A1 (en)	1997-12-04
PT910399E (pt)	2002-11-29
AU715571B2 (en)	2000-02-03
WO1997045135A1 (en)	1997-12-04
DE69715414D1 (de)	2002-10-17
DK0910399T3 (da)	2003-01-06
ES2183170T3 (es)	2003-03-16
EP0910399B1 (de)	2002-09-11
JPH10212241A (ja)	1998-08-11

Legal Events

Date

Code

Title

Description

2003-03-15

UEP

Publication of translation of european patent specification

Ref document number: 0910399

Country of ref document: EP

2012-02-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69715414D1 (de)	2002-10-17	Stabilisierte pharmazeutische zusammensetzung von bdnf
ES2563677T3 (es)	2016-03-15	Composiciones de combinaciones de Neisseria
NO934355L (no)	1993-12-01	Proteinformulering omfattende veksthormon
ATE218579T1 (de)	2002-06-15	Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
NO993709L (no)	1999-09-28	Stabilisert blanding omfattende fibrinogen
ATE146360T1 (de)	1997-01-15	Gonadotropin enthaltende gefriergetrocknete troepfen
KR950703987A (ko)	1995-11-17	G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
DE59306544D1 (de)	1997-07-03	Verwendungen von alpha-Hydroxyfettsäuren
KR890004718A (ko)	1989-05-09	안정한 인체 단백질의 제조
DE59905954D1 (de)	2003-07-17	Dialkylfumarate zur behandlung von autoimmunerkrankungen
DK1017413T3 (da)	2003-02-03	Flydende formulering af interferon-beta
BR0004884A (pt)	2001-06-19	Composições acaricidas
DE69934179D1 (de)	2007-01-11	Zusammensetzung enthaltend, ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure, zur Verwendung in der Immunisierung
DK0641216T3 (da)	1998-01-26	Farmaceutisk præparat indeholdende IL-6
ES2187820T3 (es)	2003-06-16	Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
BR9809103A (pt)	2000-08-01	Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
DK0746334T3 (da)	2001-12-27	Farmaceutisk præparat indeholdende plasminogenaktivatorer
ATE264340T1 (de)	2004-04-15	Stabilisierung von gefriergetrocknetem kuchen
ATE303816T1 (de)	2005-09-15	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
DK1074264T3 (da)	2008-11-24	Inhibitorer for neovaskularisering
PT94685A (pt)	1991-03-20	Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
DK0722325T3 (da)	2000-10-02	Præparat til behandling eller forebyggelse af herpes
BR0208879A (pt)	2004-06-29	Artigo
WO2002012336A3 (en)	2003-08-14	TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
ATE225653T1 (de)	2002-10-15	Neomycin/disaccharid wässerige lösung zur behandlung von enteroclysis bei hepatischer enzephalopathie